Van AkenJvan DongenHle CessieS. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis2006; 65: 20–25.
2.
ChungKCPushmanAG. Current concepts in the management of the rheumatoid hand. J Hand Surg2011; 36: 736–747.
3.
FisnikuLKBrexPAAltmannDR. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808–817.
4.
ConfavreuxCVukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain2003; 126: 770–782.
5.
LerayEYaouanqJLe PageE. Evidence for a two-stage disability progression in multiple sclerosis. Brain2010; 133: 1900–1913.
6.
ScalfariANeuhausADegenhardtA. The natural history of multiple sclerosis: a geographically based study 10. Relapses and long-term disability. Brain2010; 133: 1914–1929.
7.
GoodinDSRederATEbersGC. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology2012; 78: 1315–1322.
8.
International Multiple Sclerosis Genetics Consortium. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet2013; 45: 1353–1360.
9.
HauserSL. The Charcot Lecture: beating MS: a story of B cells, with twists and turns. Mult Scler J2015; 21: 8–21.
10.
MatsushitaTMadireddyLSprengerT. Genetic associations with brain cortical thickness in multiple sclerosis. Genes Brain Behav2015; 14: 217–227.
11.
HulstHEGeurtsJJ. Gray matter imaging in multiple sclerosis: what have we learned?BMC Neurol2011; 11: 153.
12.
CalabreseMMagliozziRCiccarelliO. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci2015; 16: 147–158.
13.
PopescuBFLucchinettiCF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol2012; 12: 11.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2014; 83: 278–286.
16.
CalabreseMRomualdiCPorettoV. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol2013; 74: 76–83.
17.
De StefanoNGiorgioABattagliniM. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology2010; 74: 1868–1876.
18.
ColesAJCoxALe PageE. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol2006; 253: 98–108.
19.
National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing–remitting multiple sclerosis, www.nice.org.uk/guidance/ta320/chapter/1-guidance (2014, accessed September 2015).
20.
ChatawayJSchuererNAlsanousiA. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet2014; 383: 2213–2221.
